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ABSTRACT
Background. Mutations in hepatocyte nuclear factor 1B (HNF1B) have been associated with congenital anomalies of the kidney
and urinary tract (CAKUT) in humans. Diabetes and other less frequent anomalies have also been described. Variable
penetrance and intrafamilial variability have been demonstrated including severe prenatal phenotypes. Thus, it is
important to differentiate this entity from others with similar clinical features and perform confirmatory molecular
diagnosis.
Methods. This study reports the results of HNF1B screening in a cohort of 60 patients from 58 unrelated families presenting
with renal structural anomalies and/or non-immune glucose metabolism alterations, and other minor features suggesting
HNF1B mutations.
Results. This study identified a pathogenic variant in 23 patients from 21 families. The most frequent finding was bilateral
cystic dysplasia or hyperechogenic kidneys (87% of patients). Sixty percent of them also fulfilled the criteria for impaired
glucose metabolism, and these were significantly older than those patients with an HNF1B mutation but without diabetes or
prediabetes (14.4 versus 3.3 years, P<0.05). Furthermore, patients with HNF1B mutations had higher frequency of pancreatic
structural anomalies and hypomagnesaemia than patients without mutations (P<0.001 and P ¼ 0.003, respectively).
Hyperuricaemia and increased liver enzymes were detected in some patients as well.
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Conclusions. Renal anomalies found in patients with HNF1B mutations are frequently unspecific and may resemble those
found in other renal pathologies (CAKUT, ciliopathies). Active searching for extrarenal minor features, especially pancreatic
structural anomalies or hypomagnesaemia, could support the indication for molecular diagnosis to identify HNF1B
mutations.
Keywords: CAKUT, HNF1B, hypomagnesaemia, MODY, pancreatic structural anomalies
INTRODUCTION
The hepatocyte nuclear factor 1B gene (HNF1B; OMIM * 189907) enc-
odes the transcription factor HNF1B, involved in the embryo-
logic development of several tissues, including kidney,
pancreas, lung, liver and gut [1]. Heterozygous mutations of this
gene were first described in patients with maturity-onset diabe-
tes of the young (MODY) [2]. Subsequently, several anomalies
have also been associated with pathogenic mutations in this
gene. Among them, congenital anomalies of the kidney and uri-
nary tract (CAKUT), mainly bilateral cystic dysplasia [3], and
MODY-type diabetes [4] are the most common. Less often, pan-
creatic or genital structural anomalies, mildly elevated liver
enzymes, hyperuricaemia and hypomagnesaemia are also
present in the affected patients [5–8]. Although in children kid-
ney disease represents the most frequent phenotype at diagno-
sis, diabetes remains the leading clinical expression in adults
[4, 9, 10].
The HNF1B gene has also been linked to ciliopathies through
its direct effect on gene regulation. Indeed, HNF1B knockout
mice diminish the expression of PKHD1 and PKD2 genes, whose
mutations are responsible for autosomal-recessive and -dominant
polycystic kidney disease (ARPKD and ADPKD), respectively [11,
12]. Both ARPKD and ADPKD are classical models of ciliopathies, a
group of diseases caused by abnormalities of genes coding for pro-
teins expressed at the primary cilium, with progressive develop-
ment of cysts in several organs.
More specifically, mutations in the HNF1B gene have also
been observed in some patients with severe and early-onset
ADPKD phenotype presenting with large hyperechogenic kid-
neys and prenatally severely impaired kidney function, mimick-
ing ARPKD [8, 13]. Seminal vesicle or epididymal cysts, as well
as moderately enlarged and cystic kidneys are also other classi-
cal findings in patients carrying HNF1B mutations, characteris-
tics that again resemble ADPKD. Different transmission
patterns of these diseases underlie the need for confirmatory
molecular diagnosis [10, 14].
Mutations in HNF1B are inherited in a dominant way with
40–60% of patients carrying a de novo mutation [3, 4]. About half
of the described mutations consist of whole heterozygous gene
deletions [15]. Variable penetrance with non-specific clinical
manifestations and a high prevalence of de novo cases compli-
cates the diagnosis. However, genetic confirmation is important
for patient and relatives due to different implications in disease
outcome and impacts on family counselling.
In this study, we aimed to diagnose HNF1B mutations in a
group of patients harbouring renal and/or glucose metabolism
alterations and described those often associated extrarenal mi-
nor clinical features. We focus on those associated phenotypic
characteristics that might guide the differential diagnosis with
CAKUT of different origin and even with cystic diseases, in or-
der to encourage early patient detection and promote genetic
confirmation of HNF1B mutations.
MATERIALS ANDMETHODS
Patients
This is a retrospective study that included 60 patients from 58
unrelated families. Blood samples were sent from 2006 to 2016
for the analysis of HNF1B, within a research project for
the clinical and molecular characterization of the alterations in
this gene. Patients’ samples were referred by several
Nephrology or Endocrinology Departments (paediatric or adults)
from different hospitals in Spain. These patients presented with
either renal structural anomalies or non-immune glucose me-
tabolism disturbances, and other minor features suggesting
HNF1B mutations: genital or pancreatic structural anomalies, el-
evated liver enzymes, hyperuricaemia, hypomagnesaemia or
family history of any of these anomalies in first- and/or second-
degree relatives. Written informed consent and clinical data
were required in all cases. The study was approved by the
Ethics Committee for Clinical Research of Euskadi.
All clinicians participating in the study were asked to fill out
a registration data form with demographic, prenatal and famil-
ial history data, and clinical data from abdominal ultrasound
(US) or computed tomography scan and biochemical analysis.
Collected clinical data included information about the presence
and grade of chronic kidney disease (CKD), alterations of carbo-
hydrate metabolism, anomalies in the serum levels of uric acid,
liver enzymes and magnesium, and description of renal, genital
and pancreatic structural anomalies.
Renal hyperechogenicity was defined as the finding of more
intense kidney than liver echogenicity by US. Renal cystic dys-
plasia was defined by the loss of corticomedullary differentia-
tion pattern and the presence of cysts. Glomerular filtration rate
was estimated using the Schwartz or Cockroft formula, in
patients <18 or >18 years, respectively [16, 17].
Diabetes and other carbohydrate metabolism disturbances
[impaired fasting glucose (IFG) or impaired glucose tolerance]
were defined following the 2014 American Diabetes Association
diagnostic criteria [18]. Pancreatic islet cell autoantibodies were
tested in all cases in our laboratory and turned out to be
negative.
Molecular analysis
After informed consent was given, peripheral blood samples
were collected for molecular analysis of the HNF1B gene at the
laboratory of the Genetic Department of BioCruces Health
Research Institute in Barakaldo, Spain. Genomic DNA was
extracted from blood leucocytes according to manufacturer’s
instructions (QIAampVR DNA Blood Mini Kit, QIAGEN, Germany).
Copy number quantification and identification of gross duplica-
tions or deletions at the HNF1B region were performed using
the multiplex ligation-dependent probe amplification technique
as previously described [19]. When no alteration was found, all
nine exons and all exon–intron boundaries of the HNF1B gene
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were analysed by polymerase chain reaction amplification and
direct sequencing [2].
Pathogenic effects of previously described DNA variants of
the HNF1B gene were assessed using Ensembl (www.ensembl.
org) and Human Gene Mutation Database (www.biobase-interna
tional.com/product/hgmd) databases. New missense DNA
variants were assessed using the following software tools
for prediction of pathogenicity: Mutation t@sting (www.muta
tiontaster.org), PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/), Sorting intolerant from tolerant (SIFT) (sift.jcvi.org) and
SNPs&GO (www.snpsand-go.biocomp.unibo.it).
Statistical analysis
Qualitative variables were described with percentages and
quantitative variables with median and interquartile range
(IQR). We compared the clinical features observed in the sub-
group of patients with HNF1B mutations versus the one without,
using the Fisher’s exact test for categorical variables and the
Mann–Whitney U test for continuous variables. All tests were
two sided. P < 0.05 was considered significant.
RESULTS
All study group
A total of 60 patients from 58 unrelated families were studied.
The main clinical findings in all patients are shown in Table 1.
Renal structural anomalies were the most common finding
(87%). Unilateral or bilateral cystic dysplasia at kidney US was
observed in 33 patients (55%), bilateral hyperechogenic kidneys
represented the main finding in eight patients (13%), and non-
cystic renal anomalies were present in 18% of the series (four
cases of unilateral agenesis and seven cases of hypo-dysplasia
without cysts).
Pancreatic anomalies were observed in 29 out of 60 patients
(48%). Of those, 27 (93%) suffered from diabetes or pre-diabetes
(IFG/impaired glucose tolerance) and 8 (28%) had structural
anomalies (partial agenesis or hypoplasia).
Hyperuricaemia was the most frequent minor anomaly
detected in the study group (32%), followed by the presence of
elevated liver enzymes (27%) and structural reproductive sys-
tem defects (22%). Finally, hypomagnesaemia was found in 23%
of them.
Subgroup of patients with HNF1Bmutations
We found HNF1B mutations in 23 patients from 21 families, that
is, in 38% of the studied patients. Those were point mutations
in 6 cases (26%), whole heterozygous deletions in 16 cases (70%)
and partial heterozygous deletions in 1 case (4%). Point muta-
tions c.589A>C and c.513G>C have not been previously reported
and were considered pathogenic based on prediction software
results. Furthermore, in 14 cases, both parents were additionally
studied concluding that in 10 of the families, mutations
appeared de novo (71%), while they were inherited from the
mother in the 4 remaining cases (29%). Eight out of 10 de novo
mutations were partial or whole heterozygous deletions.
Detailed renal and extrarenal features of patients carrying a
mutation in HNF1B are shown in Table 2. Male to female
ratio was 1.3. The median (IQR) age at diagnosis was 9.8 years
(0.1–17.2).
Renal phenotype. All but one patient had kidney anomalies on
the US. Among them, bilateral cystic dysplasia and bilateral
hyperechogenic kidneys were by far the most frequent findings
(20 of 22 patients). There was a positive prenatal history of renal
abnormalities detected by renal US during pregnancy in 53% of
the patients. The median age at diagnosis of those patients with
hyperechogenic kidneys was lower than that in patients with
other sorts of renal defect, although not significant (5.07 versus
12.02 years, P ¼ 0.16).
More than one-third of the patients with HNF1B mutations
(36%) developed moderate to severe CKD over time (CKD Stage
3). Kidney biopsy was performed in three of them, demon-
strating glomerulocystic disease and renal dysplasia (two cases)
and mild mesangial glomerulonephritis (one case). Furthermore,
in six patients, renal dysplasia was also associated with other
CAKUT findings: bilateral hydronephrosis in four cases (one ure-
teropelvic junction obstruction), and unilateral hydronephrosis
or vesicoureteral reflux in one case each.
Hyperuricaemia was a common finding and present in 29%
of the patients with mutations in HNF1B. Most of them (4/6) also
had associated moderate to severely reduced renal function,
and baseline uric acid levels at early CKD stages were not avail-
able. Finally, 53% of the patients carrying a mutation presented
with hypomagnesaemia (preserved glomerular filtration rate in
most cases).
Diabetes. More than half of the patients with HNF1B mutations
(60%) presented diabetes or prediabetes. Moreover, one diabetic
female recalled a previous history of gestational diabetes. The
median (IQR) age of onset of diabetes in those patients was
16 years (11–22 years). The median age at diagnosis of patients
with HNF1B mutations and permanent disturbances of carbohy-
drate metabolism was significantly higher compared with those
without diabetes or prediabetes (14.4 versus 3.3 years, P< 0.05).
Finally, two patients (SOR0042 and DM0729) without clinical evi-
dence of impaired glucose metabolism but with severe pancre-
atic hypoplasia developed transient diabetes early after renal
transplantation and treatment with corticosteroids and tacroli-
mus, at the age of 7 and 8 years, respectively. In both cases, dia-
betes resolved spontaneously following those drugs’ dose
reductions.
Pancreatic phenotype. More than one-third of patients with an
HNF1B mutation (35%) had pancreatic structural anomalies,
namely partial hypoplasia and cystic dysplasia. Among them,
all except two suffered from permanent diabetes or prediabetes
as well: patient DM2483, who had an agenesis of pancreas body
and tail and was 11 years old at the time of diagnosis; and pa-
tient SOR0042, who was born with a severe cystic dysplasia of
Table 1. Demographic and clinical findings in all patients
All patients: 60
(patients with available info)
Age, years, median (IQR) 20.9 (10–26)
Age at diagnosis, years, median (IQR) 8.35 (0.1–13)
Gender 1.22 (male to female ratio)
Renal structural anomalies 52/60
Diabetes/prediabetes 27/60
Hyperuricaemia 18/57
Elevated liver enzymes 16/59
Genital structural anomalies 13/60
Hypomagnesaemia 12/52
Pancreatic structural anomalies 8/60
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the pancreas and had a transitory diabetes right after renal
transplantation.
Reproductive organs phenotype. Genital structural anomalies
were present in 35% of the patients with mutations in HNF1B;
the most frequent finding was the presence of epididymal cysts
in three cases and septated uterus in two cases.
Liver phenotype. One-third of these patients (35%) had elevated
liver enzymes, with a mixed hepatocellular–cholestatic pattern
in most of them (6/8). Liver enzymes were only mildly elevated
in all cases. Three of these patients also had a hepatic steatosis.
A solitary liver cyst was also observed in one patient (DM0729).
Comparison between cases with and without HNF1B
mutations
In order to establish which clinical features were more specifi-
cally associated with HNF1B mutations, we compared the fre-
quency of the following findings between both groups (Table 3).
The presence of bilateral hyperechogenic kidneys at renal
US was significantly higher in the group of patients with HNF1B
mutations (P ¼ 0.04) although there was no difference in the fre-
quency of unilateral or bilateral cystic dysplasia between both
groups. Hypomagnesaemia and the presence of pancreatic
structural anomalies were also significantly more frequent in
the group with HNF1B mutations (P ¼ 0.003 and P< 0.001,
respectively).
We found no differences in the frequency of glucose metabo-
lism disturbances between both groups or in the age of diabetic
patients with and without mutations in HNF1B. Finally, we
found no differences in the frequency of genital structural
anomalies, liver enzymes’ anomalies or hyperuricaemia in both
groups.
DISCUSSION
In this study, we analysed the prevalence of mutations in
HNF1B in a cohort of 60 patients with renal structural anomalies
and/or alterations of glucose metabolism, and other minor fea-
tures suggestive of this syndrome. We described the molecular
variants found in this gene and the clinical findings in patients
carrying those mutations. Finally, we compared the clinical
findings between the group of patients with and without muta-
tions in this gene and suggested which features could be helpful
to distinguish this entity from other renal cystic diseases or
CAKUT. Therefore, in this study, we report a detailed phenotype
description in a large series of affected patients, adding new
knowledge of the systemic expression of HNF1B mutations.
A potential limitation of this study was the fact that samples
were sent by Endocrinologists or Nephrologists with a clinical
suspicion of HNF1B. Thus, the concern for a selection bias could
rise as clinical criteria needed for sample submission were wide
and depended on the clinician’s diagnosis. This could affect the
generalizability of our findings to other non-selected cohorts.
We identified disease-causing mutations in 23 patients from
21 unrelated families, which represent a detection rate of 38% in
this cohort. This is consistent with previous studies in which
the prevalence of HNF1B mutations in patients with isolated re-
nal structural anomalies was 21%, whereas in those with associ-
ated MODY-type diabetes it was 41% [20]. The frequency of
complete heterozygous deletions (70%) in our study was higher
than that previously published, which is 50% [15]. These differ-
ences should be interpreted with caution due to the small sam-
ple size and potential variation of diagnostic methodology.
All except one of the patients in our cohort carrying an
HNF1B mutation had renal structural anomalies. Most of those
anomalies were bilateral cystic dysplasia or bilateral hyperecho-
genic kidneys, emphasizing the importance of bilateral occur-
rence of congenital renal defects of genetic origin. The latter
finding was significantly associated with the presence of HNF1B
mutations in our cohort. Moreover, patients with hyperecho-
genic kidneys carrying a mutation were overall younger than
those with other renal anomalies. This is consistent with a pre-
vious report showing that HNF1B mutations were the most com-
mon cause of foetal bilateral hyperechogenic kidneys [13]. This
US finding is due to the presence of dysplasia with microscopic
cysts, as shown in previous studies where histological examina-
tion of these kidneys was performed [8, 21]. In our opinion, it is
crucial to consider the variability of the echographic findings of
those patients in relation to the age at diagnosis and to take
into account that renal cysts usually are not evident in younger
patients.
We found permanent glucose metabolism alterations in 60%
of patients carrying HNF1B mutations, which is similar to
45–50% prevalence of diabetes shown in previous studies [4, 20].
In addition, there were no differences in the frequency of glu-
cose metabolism alterations between patients with and without
HNF1B mutations. This could be explained by the fact that dia-
betes is very frequent in the general population, especially in
patients with CKD, and the only requirement for including dia-
betes as a major criterion in these patients was the absence of
pancreatic antibodies, thus including Type 2 diabetes. However,
in the group of patients with HNF1B mutations, diabetic patients
Table 3. Comparison of phenotypes between patients with and without HNF1B mutations (clinical characteristics were not available in all
patients)
Patients with HNF1B mutation Patients without identified mutation P value
Renal structural anomalies
Cystic dysplasia 14/23 19/37 0.47
Bilateral hyperechogenic kidneys 7/23 1/37 0.04
Pancreatic anomalies
Diabetes/prediabetes 14/23 13/37 0.51
Age, median (IQR), years 29.3 (17.5–44) 31.8 (17.5–45.5) 0.74
Pancreatic structural anomalies 8/23 0/37 <0.001
Genital structural anomalies 8/23 5/37 0.06
Elevated liver enzymes 8/22 8/37 0.22
Hyperuricaemia 6/21 12/36 0.71
Hypomagnesaemia 9/17 3/35 0.003
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were significantly older than non-diabetic patients. This is not
surprising as MODY-type diabetes in these cases usually
appears in the second and third decade of life [10, 20]. Again,
this variability in the clinical manifestations in relation to the
age at diagnosis should be taken into account: younger patients
will most probably present with renal anomalies, especially bi-
lateral hyperechogenic kidneys, and older patients will more
probably suffer additionally from impaired glucose metabolism.
The frequency of pancreatic structural anomalies in the
group of patients with HNF1B mutation was higher than that of
previous publications [7, 10, 20], and it was significantly higher
than that of patients without HNF1B mutations. This could be
explained by the fact that information from pancreatic US was
actively requested from doctors sending blood samples for
these patients. This finding has important implications as the
pancreas is an organ easily seen by US in children, even in pre-
natal US [22], and the presence of a structural anomaly in this
organ can help guiding the molecular diagnosis towards HNF1B
anomalies. Noteworthy is the case of patient SOR0042 with a se-
vere pancreatic cystic dysplasia: although the presence of pan-
creatic cysts has rarely been reported before in these patients
[8], this finding supports the molecular known relation between
HNF1B and polycystic kidney disease genes [11, 12], as pancre-
atic cysts are found in almost 10% of patients with ADPKD [23].
Although there was a higher frequency of genital structural
anomalies in patients with HNF1B mutations, it was not signifi-
cantly different from that of the patients without mutations.
There is a known association between congenital renal and gen-
ital anomalies, but as previously reported, it is not specific to
HNF1B mutations [24, 25]. This association is probably due to
the common embryologic development of renal and genital sys-
tems. However, as uterus anomalies are not frequent in patients
with polycystic kidney disease, this feature could help guiding
the molecular diagnosis in those patients with renal features
compatible with both diseases (bilateral big hyperechogenic or
cystic kidneys).
The frequency of hyperuricaemia and elevated liver
enzymes was not significantly different between patients with
and without HNF1B mutations. This is not surprising as the
prevalence of these anomalies in the general population is high,
especially in adult patients. In addition, hyperuricaemia is more
frequent in patients with CKD, as was the case of many of our
patients with renal structural anomalies. Thus, we think that
the presence of hyperuricaemia and elevated liver enzymes as a
marker of HNF1B mutations is probably more significant in
younger patients without CKD or other associated pathologies
that can be confounding.
Finally, hypomagnesaemia was present in half of the
patients carrying a mutation in HNF1B, and it was significantly
more frequent in this group. This feature has been reported be-
fore in 40% of patients with HNF1B mutations [6]. We think that
it should be actively searched for in cases of renal structural
anomalies because, although generally asymptomatic, it can
help guide the molecular diagnosis in these cases.
Hypomagnesaemia is thought to be of renal origin, as HNF1B
regulates the transcription of FXYD2, which participates in the
tubular handling of magnesium [6].
In conclusion, anomalies associated with mutations in
HNF1B support the detection of affected individuals from the
general pool of CAKUT and the indication for molecular analy-
sis. Furthermore, some clinical findings in patients with HNF1B
mutations can mimic those found in polycystic kidney disease,
thus complicating the molecular confirmation of the diagnosis.
This is important for the genetic counselling of those patients,
as the two diseases are inherited in different ways and have dif-
ferent prognoses. In our study, we showed that some minor
findings, such as pancreatic structural anomalies or hypomag-
nesaemia, can help guide the molecular diagnosis. Active
searching for those anomalies with radiologic studies and anal-
yses is crucial as they are frequently asymptomatic and over-
looked in everyday clinical practice. In addition, variability of
the clinical findings in HNF1B mutations in relation to the age of
the patient must be taken into account especially as family his-
tory will not be helpful in de novo cases.
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